A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)

Clinical trial NCT01945775 · COMPLETED

Trial details

NCT number: NCT01945775
Sponsor: Pfizer
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Breast Neoplasms BRCA 1 Gene Mutation BRCA 2 Gene Mutation

Start date: 2013-10-14
Primary completion: 2017-09-15
Enrollment: 431

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.